We all know you mean Rykster - think he'll be keeping his head down.
I hope Recce deliberately enrol some patients with known difficult to kill bacterial infections such as Pseudomonas. If they can demonstrate good results for those with the really high MICs, it would be even more of a game changer.
Disappointed that since December 2022 approval to begin trial there have only been 5 patients. I suppose that is lightening speed compared to the burns "trial". But I had always imagined these topical trials would be really fast to enrol and the turnaround time for results would be quick. Not the case it seems.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)